Back to Agenda
Regulatory Policy Roundtable: Pharmaceutical Quality, Generics, Innovative Medicines
Session Chair(s)
Aaron Josephson, MS
Senior Director, Global Regulatory Policy
Teva Pharmaceuticals, United States
Industry leaders will discuss how regulatory and industrial policy can support delivering quality-assured medicines to patients faster, how to assure pharmaceutical quality for innovative and generic medicines especially in light of new analytical technologies, and how to evaluate potential threats to quality in the context of benefit-risk and patient access.
Learning Objective : Define quality management maturity (QMM) and how the government is proposing to use it to improve the quality of medicines and resiliency of the supply chain; Identify policy solutions to quality challenges like nitrosamines, PFAS, and related impurities/chemicals; Understand the role of third parties like USP in defining quality standards; Comprehend policy ideas that enable earlier patient access to medicines without compromising quality
Speaker(s)
How to Integrate Quality Management Maturity into Regulatory Assessment and Oversight
Aaron Josephson, MS
Teva Pharmaceuticals, United States
Senior Director, Global Regulatory Policy
Global Landscape of Emerging Impurity and Chemicals Challenges
Katherine Wilson, JD, MA
Viatris, United States
Head, Global Regulatory Policy and Intelligence
Quality Policy Priorities of the Canadian Generic Industry
Kristin Willemsen, MS
Canadian Generic Pharmaceutical Association, Canada
Vice President, Scientific and Regulatory Affairs
The Changing Pharmaceutical Quality Landscape – Pharmacopeial Perspective
Brett Howard, JD, PhD
USP, United States
Senior Director, US Regulatory Policy
Have an account?